Excerpt from:
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh